Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.400 Biomarker CTD_human

Entrez Id: 4087
Gene Symbol: SMAD2
SMAD2
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.400 GeneticVariation UNIPROT

Entrez Id: 207
Gene Symbol: AKT1
AKT1
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.400 Biomarker CTD_human

Entrez Id: 4893
Gene Symbol: NRAS
NRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.400 Biomarker CTD_human

Entrez Id: 6714
Gene Symbol: SRC
SRC
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.390 Biomarker CTD_human

Entrez Id: 8313
Gene Symbol: AXIN2
AXIN2
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.360 Biomarker CTD_human

Entrez Id: 2261
Gene Symbol: FGFR3
FGFR3
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.350 Biomarker CTD_human

Entrez Id: 79695
Gene Symbol: GALNT12
GALNT12
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.320 Biomarker CTD_human

Entrez Id: 2033
Gene Symbol: EP300
EP300
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.320 Biomarker CTD_human

Entrez Id: 201163
Gene Symbol: FLCN
FLCN
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.310 Biomarker CTD_human

Entrez Id: 10395
Gene Symbol: DLC1
DLC1
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.310 Biomarker CTD_human

Entrez Id: 701
Gene Symbol: BUB1B
BUB1B
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.300 Biomarker CTD_human

Entrez Id: 4360
Gene Symbol: MRC1
MRC1
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.100 GeneticVariation BEFREE <b>Background:</b> People with germline mutation in one of the DNA mismatch repair (MMR) genes have increased colorectal cancer risk. 27811119

2018

Entrez Id: 6294
Gene Symbol: SAFB
SAFB
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.010 Biomarker BEFREE <b>Purpose:</b> To investigate the role and the underlying mechanism of scaffold attachment factor B (<i>SAFB</i>) in the progression of colorectal cancer (CRC).<b>Experimental Design:</b> SAFB expression was analyzed in the Cancer Outlier Profile Analysis of Oncomine and in 175 paraffin-embedded archived CRC tissues. 28912140

2018

Entrez Id: 673
Gene Symbol: BRAF
BRAF
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.400 GeneticVariation BEFREE <b/> BRAF mutations in colorectal cancer portend a poor prognosis, with first-line treatment often involving triplet or quadruplet chemotherapy, and single-agent targeted therapy with BRAF inhibitors failing to demonstrate clinical activity. 28576843

2018

Entrez Id: 8658
Gene Symbol: TNKS
TNKS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.030 Biomarker BEFREE <i>APC</i> Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer. 28179481

2017

Entrez Id: 5599
Gene Symbol: MAPK8
MAPK8
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.050 AlteredExpression BEFREE (-)-Epigallocatechin-3-gallate promotes pro-matrix metalloproteinase-7 production via activation of the JNK1/2 pathway in HT-29 human colorectal cancer cells. 15860507

2005

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.400 Biomarker BEFREE (18)F-FDG PET/CT scans may be useful for predicting the KRAS status of metastatic CRC and help in determining the therapeutic strategies against metastatic CRC. 26135109

2015

Entrez Id: 1738
Gene Symbol: DLD
DLD
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.100 Biomarker BEFREE (2) Upon direct in vitro coculture TRAIL-MSC induced apoptosis in TRAIL-sensitive CRC-cell lines (DLD-1 and HCT-15) but also in CRC-cell lines resistant to soluble TRAIL (HCT-8 and SW480). 19508388

2011

Entrez Id: 8743
Gene Symbol: TNFSF10
TNFSF10
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.400 Biomarker BEFREE (3) In mixed subcutaneous (s.c.) xenografts TRAIL-MSC inhibited CRC-tumour growth presumably by apoptosis induction but a substantial proportion of TRAIL-MSC within the total tumour cell number was needed to yield such anti-tumour effect. 19508388

2011

Entrez Id: 6935
Gene Symbol: ZEB1
ZEB1
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.100 AlteredExpression BEFREE (4) This transient loss is not only due to proteolytic breakdown but to a down-regulated synthesis and linked to an epithelial-mesenchymal transition (EMT) in tumor cells, and, thereby, zinc-finger-enhancer protein 1 (ZEB1) is the crucial transcriptional repressor of BM components in CRCs. 16952552

2006

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.400 Biomarker BEFREE - To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. 28165284

2017

Entrez Id: 3569
Gene Symbol: IL6
IL6
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.100 GeneticVariation BEFREE -174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. 12796383

2004

Entrez Id: 4015
Gene Symbol: LOX
LOX
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.060 Biomarker BEFREE 12(S)-Lipoxygenase (LOX) and its product 12(S)-hydroxyeicosatetraenic (HETE) acid have been implicated in angiogenesis and tumour invasion in several tumour types while their role in colorectal cancer progression has not yet been studied. 22237009

2012

Entrez Id: 7298
Gene Symbol: TYMS
TYMS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.400 Biomarker CTD_human 134 formalin-fixed and paraffin-embedded specimens of colorectal carcinoma obtained during operation from 134 patients, 65 males and 69 females, aged 34 approximately 76 with an average age of 51 +/- 11, 16 with differentiated carcinoma and 118 with undifferentiated carcinoma, 4 with infiltration into mucous layer, 21 into submucous layer, 100 into muscular layer, and 5 into serous layer, 25 without lymphatic metastasis and 109 with lymphatic metastasis, 4 in stage IB, 15 in stage II, 90 in stage IIIA, and 27 in stage IIIB by Dukes staging, underwent immunohistochemistry (ABC methods) to determine the expression of TS. 15500737

2005